Cargando…
Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials
BACKGROUND: Negative symptoms are a core aspect of psychopathology in schizophrenia. Currently available pharmacological agents have proven minimally efficacious for remediating negative symptoms. A promising treatment avenue is the intranasal administration of the neuropeptide oxytocin. However, th...
Autores principales: | Sabe, Michel, Zhao, Nan, Crippa, Alessio, Strauss, Gregory P, Kaiser, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378078/ https://www.ncbi.nlm.nih.gov/pubmed/33890987 http://dx.doi.org/10.1093/ijnp/pyab020 |
Ejemplares similares
-
Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
por: Sabe, Michel, et al.
Publicado: (2021) -
The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report
por: Lee, Mary R., et al.
Publicado: (2019) -
O7.3. DOSE-RESPONSE META-ANALYSIS TO IDENTIFY THE OPTIMUM AND EQUIVALENT DOSES OF ANTIPSYCHOTIC DRUGS FOR SCHIZOPHRENIA
por: Leucht, Stefan, et al.
Publicado: (2018) -
Dose-response meta-analysis of differences in means
por: Crippa, Alessio, et al.
Publicado: (2016) -
EPA guidance on treatment of negative symptoms in schizophrenia
por: Galderisi, S., et al.
Publicado: (2021)